Article thumbnail

Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase

By Anna C. Haagsma, Ioana Podasca, Anil Koul, Koen Andries, Jerome Guillemont, Holger Lill and Dirk Bald


Infections with Mycobacterium tuberculosis are substantially increasing on a worldwide scale and new antibiotics are urgently needed to combat concomitantly emerging drug-resistant mycobacterial strains. The diarylquinoline TMC207 is a highly promising drug candidate for treatment of tuberculosis. This compound kills M. tuberculosis by binding to a new target, mycobacterial ATP synthase. In this study we used biochemical assays and binding studies to characterize the interaction between TMC207 and ATP synthase. We show that TMC207 acts independent of the proton motive force and does not compete with protons for a common binding site. The drug is active on mycobacterial ATP synthesis at neutral and acidic pH with no significant change in affinity between pH 5.25 and pH 7.5, indicating that the protonated form of TMC207 is the active drug entity. The interaction of TMC207 with ATP synthase can be explained by a one-site binding mechanism, the drug molecule thus binds to a defined binding site on ATP synthase. TMC207 affinity for its target decreases with increasing ionic strength, suggesting that electrostatic forces play a significant role in drug binding. Our results are consistent with previous docking studies and provide experimental support for a predicted function of TMC207 in mimicking key residues in the proton transfer chain and blocking rotary movement of subunit c during catalysis. Furthermore, the high affinity of TMC207 at low proton motive force and low pH values may in part explain the exceptional ability of this compound to efficiently kill mycobacteria in different microenvironments

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.
  2. (2005). A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
  3. (2010). ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction.
  4. (1998). ATP synthesis by F0F1-ATP synthase independent of noncatalytic nucleotide binding sites and insensitive to azide inhibition.
  5. (1995). ATP synthesis catalyzed by the mitochondrial F1-F0 ATP synthase is not a reversal of its ATPase activity.
  6. (2006). Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
  7. (2006). Conformational analysis of R207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach.
  8. (2008). Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis.
  9. (2007). Diarylquinolines target subunit c of mycobacterial ATP synthase.
  10. (1997). Direct observation of the rotation of F1-ATPase.
  11. (2006). Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.
  12. (2010). Global tuberculosis drug development pipeline: the need and the reality.
  13. (2003). Immune evasion by Mycobacterium tuberculosis: living with the enemy.
  14. (2007). In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.
  15. (2010). Koul A
  16. (2004). M. tuberculosis persistence, latency, and drug tolerance.
  17. (2010). Microscopic rotary mechanism of ion translocation in the F(o) complex of ATP synthases.
  18. (2010). Multidrugresistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.
  19. (2007). Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
  20. (2010). Nutrient-starved, nonreplicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability.
  21. (1997). On the role of Arg-210 and Glu-219 of subunit a in proton translocation by the Escherichia coli F0F1-ATP synthase.
  23. (2004). Proton-powered subunit rotation in single membrane-bound F0F1-ATP synthase.
  24. (2010). Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.
  25. (2008). Regulatory mechanisms of proton-translocating F(O)F(1)-ATP synthase.
  26. (2009). Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.
  27. (2007). Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
  28. (1993). The binding change mechanism for ATP synthase–some probabilities and possibilities.
  29. (2011). The challenge of new drug discovery for tuberculosis.
  30. (2003). The curious characteristics of pyrazinamide: a review.
  31. (2009). The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
  32. (2005). The F1F0-ATP synthase of Mycobacterium smegmatis is essential for growth.
  33. (1999). The noncatalytic site-deficient alpha3beta3gamma subcomplex and FoF1-ATP synthase can continuously catalyse ATP hydrolysis when Pi is present.
  34. (2010). The population dynamics and control of tuberculosis.
  35. (2008). The proton motive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis.
  36. (2009). Torque generation and elastic power transmission in the rotary F(O)F(1)-ATPase.
  37. (2010). Tuberculosis: what we don’t know can, and does, hurt us.
  38. (2010). Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia.
  39. (2007). Virtually incurable TB warns of impending disaster.